---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343408"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2026-08-11T11:05:26+00:00"
generated_at: "2026-08-11T11:10:35.854415+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aura cuts 20% workforce, refocuses on ocular oncology; Q2 cash $323.8M

## Summary
- Q2 2026 cash and equivalents $323.8M; R&D expense $30.7M (up from $22.9M YoY).
- Phase 3 CoMpass fully enrolled (108 patients); topline data expected 2H 2027.
- Workforce reduction ~20% with $2.9-3.2M estimated costs; NMIBC program deprioritized.
- CFO Tony Gibney departs Sept 1, 2026; Amy Elazzouzi named interim principal financial officer.
- Susan Abu-Absi appointed COO; base salary $520K and equity award ~400K shares.

## SEC filing metadata
- accession: 0001193125-26-343408
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2026-08-11T11:05:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/0001193125-26-343408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/aura-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343408
- JSON: https://secwatch.observer/filing/0001193125-26-343408.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.